This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
liver disease | 1202 |
liver failure | 904 |
liver injury | 681 |
liver transplantation | 634 |
chronic hepatitis | 601 |
acute liver | 451 |
chronic liver | 391 |
fatty liver | 337 |
hepatic encephalopathy | 308 |
liver function | 303 |
clinical signs | 294 |
hepatocellular carcinoma | 289 |
liver diseases | 272 |
mg kg | 261 |
portal hypertension | 258 |
severe hepatitis | 254 |
liver fibrosis | 246 |
hbv dna | 241 |
portal vein | 228 |
liver cirrhosis | 216 |
liver biopsy | 210 |
risk factors | 193 |
hepatic failure | 190 |
blood flow | 188 |
bile duct | 168 |
liver transplant | 168 |
hcv rna | 161 |
nonalcoholic fatty | 154 |
induced liver | 146 |
may also | 141 |
liver damage | 141 |
stem cells | 138 |
bile acids | 137 |
fulminant hepatic | 126 |
critically ill | 126 |
growth factor | 125 |
significantly higher | 122 |
hbv infection | 121 |
oxidative stress | 121 |
copies ml | 120 |
amino acids | 119 |
hepatic fibrosis | 117 |
viral hepatitis | 116 |
gene expression | 114 |
acute hepatitis | 111 |
alcoholic fatty | 110 |
liver tissue | 109 |
kupffer cells | 107 |
body weight | 102 |
abdominal pain | 101 |
cirrhotic patients | 100 |
hepatorenal syndrome | 99 |
insulin resistance | 99 |
two groups | 98 |
novel coronavirus | 98 |
liver cells | 97 |
serum alt | 96 |
united states | 96 |
renal failure | 96 |
hcv infection | 95 |
liver enzymes | 95 |
side effects | 95 |
bile ducts | 94 |
viral load | 94 |
weight loss | 92 |
hepatic injury | 92 |
biliary tract | 92 |
clinical characteristics | 91 |
coronavirus disease | 90 |
hepatic disease | 89 |
peripheral blood | 89 |
control group | 89 |
diabetes mellitus | 88 |
liver oil | 88 |
immune response | 88 |
inflammatory response | 87 |
hepatic lipidosis | 87 |
one study | 87 |
nonalcoholic steatohepatitis | 87 |
mesenchymal stem | 87 |
portosystemic shunts | 85 |
amino acid | 85 |
liver dysfunction | 84 |
cod liver | 84 |
important role | 83 |
intensive care | 83 |
liver cancer | 82 |
mg dl | 81 |
may occur | 81 |
hepatic copper | 80 |
regulated proteins | 79 |
bile acid | 77 |
portosystemic shunting | 76 |
reperfusion injury | 75 |
liver cell | 75 |
liver regeneration | 75 |
alt activity | 74 |
hepatic necrosis | 74 |
significant difference | 74 |
bone marrow | 74 |
transplant recipients | 74 |
may cause | 74 |
risk factor | 74 |
severe covid | 73 |
liver enzyme | 72 |
combination therapy | 72 |
stellate cells | 72 |
physical examination | 72 |
hepatobiliary disease | 72 |
small intestine | 71 |
present study | 71 |
fatty acids | 71 |
stage liver | 70 |
adverse events | 69 |
severe liver | 69 |
alanine aminotransferase | 69 |
clinical manifestations | 68 |
blood pressure | 68 |
acute respiratory | 68 |
serum hbv | 68 |
clinical features | 68 |
total bilirubin | 66 |
ill patients | 66 |
mean age | 65 |
hepatic stellate | 64 |
chb patients | 64 |
cell death | 64 |
doc id | 64 |
cord uid | 64 |
foreign bodies | 63 |
meld score | 63 |
increased risk | 62 |
patients undergoing | 62 |
orthotopic liver | 62 |
clinical trial | 62 |
may lead | 61 |
log copies | 61 |
virus infection | 61 |
may develop | 61 |
bacterial peritonitis | 61 |
disease progression | 60 |
significantly increased | 60 |
cardiac output | 60 |
patients without | 60 |
cell lines | 60 |
cell line | 59 |
alcoholic steatohepatitis | 59 |
clinical trials | 59 |
background aims | 59 |
portal venous | 59 |
prothrombin time | 58 |
infected patients | 58 |
retrospective study | 58 |
nitric oxide | 58 |
controlled trial | 57 |
immune system | 57 |
spontaneous bacterial | 57 |
may result | 56 |
alkaline phosphatase | 56 |
antiviral therapy | 56 |
systematic review | 56 |
type diabetes | 56 |
among patients | 56 |
increased serum | 56 |
flow cytometry | 55 |
blood loss | 55 |
acute hepatic | 55 |
disease severity | 55 |
liver biopsies | 55 |
coagulation factors | 55 |
definitive diagnosis | 54 |
gastrointestinal tract | 54 |
endothelial cells | 54 |
cell proliferation | 54 |
blood ammonia | 54 |
severe acute | 53 |
skeletal muscle | 53 |
positive patients | 53 |
stem cell | 53 |
clinical practice | 52 |
hepatic steatosis | 52 |
associated liver | 52 |
alt levels | 51 |
one patient | 51 |
vena cava | 51 |
protein expression | 51 |
serum bile | 51 |
congenital pss | 51 |
gastrointestinal bleeding | 51 |
small cell | 51 |
patients treated | 51 |
organ failure | 51 |
commonly used | 51 |
liver fat | 50 |
hcc patients | 50 |
epithelial cells | 50 |
dna levels | 50 |
inflammatory bowel | 50 |
bowel disease | 50 |
foreign body | 50 |
renal function | 49 |
statistically significant | 49 |
aspartate aminotransferase | 49 |
systemic circulation | 49 |
acute pancreatitis | 49 |
early stage | 48 |
iu ml | 48 |
survival rate | 48 |
cell responses | 48 |
viral infection | 48 |
underlying cause | 47 |
poor prognosis | 47 |
portal blood | 47 |
healthy controls | 47 |
abnormal liver | 47 |
hcv genotype | 47 |
randomized controlled | 47 |
mortality rate | 47 |
alp activity | 47 |
hepatic dysfunction | 47 |
see table | 47 |
lc patients | 47 |
smooth muscle | 47 |
chronic hcv | 47 |
function tests | 46 |
chronic hbv | 46 |
respiratory distress | 46 |
alcoholic liver | 46 |
type i | 46 |
mechanical ventilation | 46 |
hbeag negative | 46 |
hbeag seroconversion | 46 |
serum bilirubin | 45 |
liver resection | 45 |
hcv core | 45 |
bedlington terriers | 45 |
patients infected | 45 |
bacterial infection | 45 |
every hours | 44 |
nucleic acid | 44 |
another study | 44 |
platelet count | 44 |
advanced fibrosis | 44 |
hepatic artery | 44 |
respiratory syndrome | 44 |
virologic response | 44 |
care unit | 44 |
related liver | 44 |
pulmonary vascular | 43 |
systemic inflammatory | 43 |
recent study | 43 |
lopinavir ritonavir | 43 |
metabolic acidosis | 43 |
copper accumulation | 43 |
donor liver | 43 |
hbeag positive | 43 |
lymph nodes | 42 |
primary liver | 42 |
affected dogs | 42 |
hepatopulmonary syndrome | 42 |
supportive care | 42 |
disease may | 42 |
portal pressure | 41 |
chain reaction | 41 |
clinical outcomes | 41 |
common bile | 41 |
kupffer cell | 41 |
three groups | 41 |
dendritic cells | 41 |
intrahepatic cholestasis | 41 |
cell lymphoma | 41 |
acute exacerbation | 41 |
advanced liver | 41 |
hepatic function | 41 |
serum creatinine | 41 |
serum levels | 41 |
arterial blood | 41 |
autoimmune hepatitis | 41 |
fatty acid | 40 |
case series | 40 |
significantly decreased | 40 |
multivariate analysis | 40 |
multiple organ | 40 |
significant differences | 40 |
normal liver | 40 |
liver grafts | 40 |
factors associated | 39 |
immune responses | 39 |
portosystemic shunt | 39 |
doberman pinschers | 39 |
patients receiving | 39 |
cell activation | 39 |
patients may | 39 |
dna level | 39 |
dcd lt | 39 |
vascular resistance | 39 |
hospital stay | 39 |
additional file | 39 |
hepatitis patients | 38 |
severe disease | 38 |
kg day | 38 |
positive cells | 38 |
decompensated cirrhosis | 38 |
nervous system | 38 |
predictive value | 38 |
congenital portosystemic | 38 |
partial hepatectomy | 38 |
intracranial pressure | 38 |
venous pressure | 38 |
cerebral edema | 38 |
nk cells | 38 |
plasminogen activator | 37 |
transgenic mice | 37 |
high risk | 37 |
infectious diseases | 37 |
transplant patients | 37 |
scoring system | 37 |
upper limit | 37 |
hcv replication | 36 |
extracellular matrix | 36 |
ml kg | 36 |
intravascular coagulation | 36 |
hepatic diseases | 36 |
significantly different | 36 |
normal range | 36 |
polymerase chain | 36 |
hepatic abscesses | 36 |
chinese medicine | 36 |
distress syndrome | 36 |
prospective study | 35 |
elevated liver | 35 |
innate immune | 35 |
growth factors | 35 |
specific cd | 35 |
enzyme activity | 35 |
ng ml | 35 |
magnetic resonance | 35 |
small intestinal | 35 |
heart failure | 35 |
hepatic cirrhosis | 34 |
infected cells | 34 |
bacterial infections | 34 |
clotting factors | 34 |
gastrointestinal disease | 34 |
significantly lower | 34 |
time pcr | 34 |
necrosis factor | 34 |
fungal infection | 34 |
long term | 34 |
pg ml | 34 |
enzyme activities | 34 |
previous studies | 34 |
caudal vena | 34 |
chain amino | 34 |
results suggest | 34 |
common cause | 34 |
neonatal foals | 34 |
response syndrome | 34 |
binding protein | 34 |
needle aspiration | 34 |
logistic regression | 34 |
nafld patients | 33 |
core protein | 33 |
liver tissues | 33 |
high mortality | 33 |
two patients | 33 |
fulminant liver | 33 |
per day | 33 |
biopsy specimens | 33 |
liver insufficiency | 33 |
animal models | 33 |
traditional chinese | 33 |
cardiac death | 33 |
recent studies | 33 |
ml min | 33 |
chronic hepatic | 33 |
brain edema | 33 |
adefovir dipivoxil | 33 |
clinical course | 33 |
see chapter | 33 |
linear foreign | 33 |
regression analysis | 33 |
blood cell | 32 |
may play | 32 |
biopsy samples | 32 |
liver support | 32 |
venous blood | 32 |
hepatic tissue | 32 |
tumor necrosis | 32 |
severe hepatic | 32 |
type hepatitis | 32 |
patients received | 32 |
disseminated intravascular | 32 |
serum albumin | 32 |
public health | 32 |
graft survival | 32 |
na levertransplantatie | 32 |
increased liver | 32 |
study group | 31 |
body mass | 31 |
dry weight | 31 |
fat diet | 31 |
urinary tract | 31 |
hepatic arterial | 31 |
renal dysfunction | 31 |
adverse effects | 31 |
liver iri | 31 |
fulminant hepatitis | 31 |
esophageal varices | 31 |
refractory ascites | 31 |
group ii | 31 |
median age | 31 |
clinical significance | 31 |
acute rejection | 31 |
many cases | 31 |
group i | 31 |
rat liver | 31 |
significantly regulated | 31 |
biliary obstruction | 31 |
gut microbiota | 31 |
closely related | 31 |
within weeks | 30 |
hepatic resection | 30 |
diagnostic criteria | 30 |
mass index | 30 |
hepg cells | 30 |
large number | 30 |
patients showed | 30 |
carbon tetrachloride | 30 |
clinical symptoms | 30 |
viral clearance | 30 |
kg po | 30 |
variceal bleeding | 30 |
serum alp | 30 |
vein thrombosis | 30 |
derived mesenchymal | 30 |
intrahepatic portosystemic | 30 |
cancer cells | 30 |
fibrosis stage | 30 |
lipid peroxidation | 30 |
cell cycle | 30 |
study showed | 30 |
mononuclear cells | 30 |
laboratory tests | 30 |
septic shock | 30 |
abdominal cavity | 29 |
may include | 29 |
blood cells | 29 |
hepatic parenchyma | 29 |
within days | 29 |
blood coagulation | 29 |
year survival | 29 |
surface antigen | 29 |
controlled study | 29 |
reactive oxygen | 29 |
viral replication | 29 |
well tolerated | 29 |
independent risk | 29 |
induced hepatic | 29 |
case report | 29 |
liver inflammation | 29 |
gene silencing | 29 |
human liver | 28 |
viral response | 28 |
years old | 28 |
one case | 28 |
coagulation factor | 28 |
hepatic blood | 28 |
intestinal tract | 28 |
determine whether | 28 |
virological response | 28 |
transforming growth | 28 |
clinical findings | 28 |
western blot | 28 |
phase ii | 28 |
hbv replication | 28 |
respiratory tract | 28 |
cd cd | 28 |
copper concentrations | 27 |
cell damage | 27 |
alt normalization | 27 |
gene promoter | 27 |
survival time | 27 |
inflammatory cells | 27 |
early diagnosis | 27 |
drug resistance | 27 |
hepatic inflammation | 27 |
response rates | 27 |
electron microscopy | 27 |
clinical study | 27 |
oral administration | 27 |
intestinal mucosa | 27 |
living donor | 27 |
negative patients | 27 |
minimal hepatic | 27 |
vascular endothelial | 27 |
metabolic alkalosis | 27 |
young dogs | 27 |
cohort study | 27 |
significantly reduced | 27 |
patient survival | 27 |
red blood | 27 |
higher risk | 27 |
treated rats | 27 |
intestinal epithelial | 27 |
hepatic damage | 27 |
kg body | 27 |
oxygen species | 27 |
viral infections | 27 |
recent years | 27 |
bacterial translocation | 27 |
fungal infections | 27 |
clinical studies | 27 |
findings include | 27 |
increased significantly | 27 |
metabolic disorders | 27 |
ammonia concentration | 27 |
organ dysfunction | 27 |
tumour specific | 27 |
inflammatory cytokines | 27 |
feline infectious | 26 |
lipid nanoparticles | 26 |
several studies | 26 |
widely used | 26 |
extrahepatic biliary | 26 |
nodular hyperplasia | 26 |
signs may | 26 |
differential diagnosis | 26 |
pegylated interferon | 26 |
energy metabolism | 26 |
endoplasmic reticulum | 26 |
inflammatory reaction | 26 |
left ventricular | 26 |
converting enzyme | 26 |
even though | 26 |
stellate cell | 26 |
also occur | 26 |
may increase | 26 |
cholestatic liver | 26 |
liver stiffness | 26 |
inhibitory effect | 26 |
acid concentrations | 26 |
neonatal foal | 26 |
fat content | 26 |
treatment response | 26 |
may require | 26 |
disease regulated | 26 |
blood vessels | 26 |
gastric emptying | 26 |
hcc cell | 26 |
mg day | 26 |
factor vii | 25 |
muscle mass | 25 |
also known | 25 |
antibiotic therapy | 25 |
uric acid | 25 |
liver graft | 25 |
liver may | 25 |
may contribute | 25 |
blood transfusion | 25 |
university hospital | 25 |
existing liver | 25 |
urea cycle | 25 |
computed tomography | 25 |
cell count | 25 |
sinusoidal endothelial | 25 |
hcv infected | 25 |
following liver | 25 |
membrane potential | 25 |
lipid metabolism | 25 |
bridging necrosis | 25 |
duct obstruction | 25 |
significant increase | 25 |
pilot study | 25 |
bacterial overgrowth | 25 |
normal alt | 24 |
kidney injury | 24 |
disease process | 24 |
survival rates | 24 |
primary biliary | 24 |
hyaluronic acid | 24 |
laboratory findings | 24 |
sp cells | 24 |
syndrome coronavirus | 24 |
pleural effusion | 24 |
kidney disease | 24 |
mrna expression | 24 |
blood glucose | 24 |
cirrhotic rats | 24 |
blood samples | 24 |
coronavirus pneumonia | 24 |
mouse model | 24 |
significantly associated | 24 |
cause liver | 24 |
feline liver | 24 |
lipid nanoparticle | 24 |
may provide | 24 |
nkt cells | 24 |
infectious peritonitis | 24 |
cell membrane | 24 |
diagnostic value | 24 |
mg daily | 24 |
nutritional support | 23 |
like receptor | 23 |
dynamic changes | 23 |
abdominal radiographs | 23 |
massive necrosis | 23 |
early stages | 23 |
also found | 23 |
medical management | 23 |
alt level | 23 |
serum il | 23 |
high fat | 23 |
free survival | 23 |
analysis showed | 23 |
dna methylation | 23 |
hbv related | 23 |
effective treatment | 23 |
dependent manner | 23 |
abdominal ultrasound | 23 |
severe cases | 23 |
least one | 23 |
serum liver | 23 |
hospitalized patients | 23 |
congenital hepatic | 23 |
failure patients | 23 |
large bowel | 23 |
metabolic syndrome | 23 |
beneficial effects | 23 |
progenitor cells | 23 |
clinical data | 23 |
hepatic insufficiency | 23 |
core promoter | 23 |
genotype patients | 23 |
hepatic involvement | 23 |
hcv patients | 23 |
intrahepatic bile | 23 |
descriptive study | 23 |
fibrosis score | 23 |
hcc development | 23 |
elevated levels | 23 |
within months | 23 |
mortality rates | 23 |
phase i | 23 |
transjugular intrahepatic | 23 |
anhepatic stage | 23 |
may present | 23 |
ursodeoxycholic acid | 22 |
mrna levels | 22 |
prognostic factors | 22 |
term survival | 22 |
west highland | 22 |
insulin sensitivity | 22 |
healthy subjects | 22 |
gene therapy | 22 |
significant decrease | 22 |
acute onset | 22 |
active hepatitis | 22 |
peginterferon alfa | 22 |
response rate | 22 |
peritoneal fluid | 22 |
intestinal disease | 22 |
tract infection | 22 |
new york | 22 |
mucous membranes | 22 |
ide analogues | 22 |
muscle actin | 22 |
systemic inflammation | 22 |
differentially expressed | 22 |
animal model | 22 |
intestinal flora | 22 |
intestinal obstruction | 22 |
clinical presentation | 22 |
hepatic lesions | 22 |
free radicals | 22 |
gastric acid | 22 |
ischemia reperfusion | 22 |
three times | 22 |
stimulating factor | 22 |
immune function | 22 |
heart rate | 22 |
diagnostic accuracy | 22 |
hepatocyte transplantation | 22 |
tumor growth | 22 |
hepatic metabolism | 22 |
intestinal wall | 22 |
different stages | 22 |
six patients | 22 |
significant reduction | 22 |
renal disease | 22 |
spectrum antibiotics | 22 |
blood volume | 22 |
retrospective analysis | 22 |
one year | 22 |
drug interactions | 22 |
pregnant women | 22 |
combination treatment | 22 |
highland white | 22 |
hepatic coma | 22 |
increased levels | 22 |
signaling pathway | 21 |
performed using | 21 |
undergoing liver | 21 |
respiratory alkalosis | 21 |
high levels | 21 |
dcd liver | 21 |
activity may | 21 |
gastric ulcers | 21 |
ischemic hepatitis | 21 |
upper respiratory | 21 |
needle biopsy | 21 |
affected cats | 21 |
mast cell | 21 |
hepatoprotective activity | 21 |
cirrhosis patients | 21 |
examination findings | 21 |
cell transplantation | 21 |
intracranial hypertension | 21 |
studies showed | 21 |
oxygen saturation | 21 |
expression levels | 21 |
dose reduction | 21 |
within hours | 21 |
medicinal plants | 21 |
high level | 21 |
induced hepatotoxicity | 21 |
graft failure | 21 |
many cats | 21 |
medical records | 21 |
septic peritonitis | 21 |
vascular dilatation | 21 |
hepatic regeneration | 21 |
chronic pancreatitis | 21 |
pulmonary hypertension | 21 |
central nervous | 21 |
three patients | 21 |
antiviral drugs | 21 |
reduced hepatic | 21 |
liver resections | 21 |
failure caused | 21 |
elevated serum | 21 |
two weeks | 21 |
central venous | 21 |
cats may | 21 |
chronic inflammation | 21 |
general population | 21 |
signal transduction | 21 |
critical care | 21 |
obstructive jaundice | 21 |
pancreatic disease | 21 |
also observed | 21 |
complete blood | 21 |
odds ratio | 21 |
bile salts | 20 |
bile flow | 20 |
data suggest | 20 |
coronary artery | 20 |
liver parenchyma | 20 |
gastrointestinal symptoms | 20 |
healthy cats | 20 |
tritrichomonas foetus | 20 |
gi tract | 20 |
proton pump | 20 |
decompensated liver | 20 |
adipose tissue | 20 |
previously reported | 20 |
medical center | 20 |
albumin dialysis | 20 |
increased expression | 20 |
white blood | 20 |
acid metabolism | 20 |
connective tissue | 20 |
serum sodium | 20 |
ultrasonographic findings | 20 |
hepatic ischemia | 20 |
hbv carriers | 20 |
ast levels | 20 |
small amount | 20 |
liver steatosis | 20 |
ascitic fluid | 20 |
copper toxicosis | 20 |
infected livers | 20 |
hepatic venous | 20 |
peritoneal cavity | 20 |
breast cancer | 20 |
gastric ulceration | 20 |
serum level | 20 |
major role | 20 |
important factor | 20 |
confidence interval | 20 |
inflammatory liver | 20 |
underlying liver | 20 |
negative bacteria | 20 |
older cats | 20 |
significant correlation | 20 |
liver involvement | 20 |
escherichia coli | 20 |
chronic severe | 20 |
molecular weight | 19 |
also cause | 19 |
hbv genotype | 19 |
small bowel | 19 |
without liver | 19 |
wide range | 19 |
labrador retrievers | 19 |
elevated alt | 19 |
general anesthesia | 19 |
pulmonary edema | 19 |
arterial pressure | 19 |
may become | 19 |
liver tests | 19 |
oxygen delivery | 19 |
infected hepatocytes | 19 |
obese patients | 19 |
activated hscs | 19 |
clinically significant | 19 |
rat model | 19 |
acute kidney | 19 |
overall survival | 19 |
intestinal bacterial | 19 |
endothelial growth | 19 |
inflammatory mediators | 19 |
acute phase | 19 |
north america | 19 |
weight gain | 19 |
infection may | 19 |
human hepatocellular | 19 |
type ii | 19 |
parenchymal cells | 19 |
chronic disease | 19 |
pancreatic duct | 19 |
underlying disease | 19 |
upper gastrointestinal | 19 |
cytokine storm | 19 |
otitis media | 19 |
hepatic enzyme | 19 |
plasma levels | 19 |
common clinical | 19 |
ammonia levels | 19 |
different types | 19 |
high serum | 19 |
umbilical cord | 19 |
biliary cirrhosis | 19 |
artificial liver | 19 |
treated patients | 19 |
therapeutic efficacy | 19 |
age years | 19 |
epidermal growth | 19 |
adult liver | 19 |
molecular adsorbent | 19 |
hepatic veins | 19 |
pathological changes | 19 |
copper content | 19 |
cell types | 19 |
surgical resection | 19 |
decreased significantly | 19 |
expression level | 19 |
peroxisome proliferator | 18 |
density lipoprotein | 18 |
biliary tree | 18 |
mean arterial | 18 |
transit time | 18 |
analysis revealed | 18 |
world health | 18 |
gold standard | 18 |
rna level | 18 |
median survival | 18 |
diabetic patients | 18 |
plus ribavirin | 18 |
circulatory death | 18 |
background aim | 18 |
preexisting liver | 18 |
decreased hepatic | 18 |
aromatic amino | 18 |
whole blood | 18 |
liver tumors | 18 |
abdominal distention | 18 |
liver histology | 18 |
innate immunity | 18 |
healthy volunteers | 18 |
kidney transplantation | 18 |
human hcc | 18 |
respiratory symptoms | 18 |
less common | 18 |
abdominal distension | 18 |
hepatocyte necrosis | 18 |
blood circulation | 18 |
commonly seen | 18 |
neurologic signs | 18 |
increased alt | 18 |
commonly associated | 18 |
natural history | 18 |
platelet counts | 18 |
lipid accumulation | 18 |
coagulation dysfunction | 18 |
several days | 18 |
biliary system | 18 |
hepatocyte growth | 18 |
advanced cirrhosis | 18 |
respiratory failure | 18 |
transcription factors | 18 |
van een | 18 |
genes involved | 18 |
cd cells | 18 |
infectious agents | 18 |
may appear | 18 |
five patients | 18 |
antiviral treatment | 18 |
liver ischemia | 18 |
hepatoma cells | 18 |
signaling pathways | 18 |
chronic active | 18 |
exocrine pancreatic | 18 |
histopathologic examination | 18 |
twice daily | 18 |
complete response | 18 |
lt recipients | 18 |
pump inhibitors | 18 |
protein kinase | 18 |
fibrosis progression | 18 |
observational study | 18 |
blood donors | 18 |
intestinal permeability | 18 |
therapy may | 18 |
induced acute | 17 |
mental status | 17 |
glomerular filtration | 17 |
solid organ | 17 |
portal hypertensive | 17 |
health organization | 17 |
ct scan | 17 |
antioxidant activity | 17 |
acute renal | 17 |
dietary supplements | 17 |
primary hepatic | 17 |
sustained virologic | 17 |
hemodynamic changes | 17 |
adult patients | 17 |
mitochondrial function | 17 |
naturally occurring | 17 |
real time | 17 |
randomized trial | 17 |
donor age | 17 |
may reveal | 17 |
common finding | 17 |
portal area | 17 |
oxide synthase | 17 |
recirculating system | 17 |
liver lobe | 17 |
wild type | 17 |
study period | 17 |
study clinical | 17 |
cell necrosis | 17 |
affected foals | 17 |
large amount | 17 |
alcoholic cirrhosis | 17 |
th cells | 17 |
patienten mit | 17 |
endothelial cell | 17 |
dcd donors | 17 |
positively correlated | 17 |
free radical | 17 |
kg iv | 17 |
normalized ratio | 17 |
cell tumors | 17 |
antiviral activity | 17 |
hepatic cells | 17 |
vascular anomalies | 17 |
glutathione peroxidase | 17 |
cellular rejection | 17 |
human hepatocytes | 17 |
findings may | 17 |
mesenteric lymph | 17 |
biochemical parameters | 17 |
significant fibrosis | 17 |
meconium impaction | 17 |
low cardiac | 17 |
urine output | 17 |
immune cells | 17 |
systemic vascular | 17 |
filtration rate | 17 |
reactive hepatitis | 17 |
iri mito | 17 |
intestinal bacteria | 17 |
dna synthesis | 17 |
molecular mechanisms | 17 |
blood mononuclear | 17 |
failure due | 17 |
international normalized | 17 |
cirrhotic liver | 17 |
protective effect | 17 |
sample size | 17 |
pancreatic insufficiency | 17 |
alcoholic hepatitis | 17 |
cancer patients | 17 |
receptor antagonist | 17 |
central role | 17 |
extrahepatic bile | 17 |
mit einer | 17 |
immunosuppressive therapy | 17 |
low dose | 17 |
severe group | 17 |
infectious disease | 16 |
radiofrequency ablation | 16 |
chronic infection | 16 |
commercially available | 16 |
osmotic pressure | 16 |
serum chemistry | 16 |
mass spectrometry | 16 |
skeletal muscles | 16 |
activated protein | 16 |
varying degrees | 16 |
hepatocellular necrosis | 16 |
tbil levels | 16 |
partial pressure | 16 |
drug reactions | 16 |
positive rate | 16 |
chronic viral | 16 |
markedly increased | 16 |
fluid therapy | 16 |
investigated whether | 16 |
significant improvement | 16 |
host immune | 16 |
alcohol consumption | 16 |
liver sections | 16 |
tumor cells | 16 |
herpes simplex | 16 |
bij een | 16 |
right upper | 16 |
hepatic vein | 16 |
increased mortality | 16 |
electrolyte abnormalities | 16 |
liver functions | 16 |
may reduce | 16 |
injury may | 16 |
transplantation using | 16 |
therapeutic effect | 16 |
master regulatory | 16 |
portosystemic vascular | 16 |
intestinal mucosal | 16 |
brain barrier | 16 |
blot analysis | 16 |
tm sf | 16 |
liver mass | 16 |
results showed | 16 |
informed consent | 16 |
pediatric liver | 16 |
pulmonary artery | 16 |
lymph node | 16 |
clinical diagnosis | 16 |
activated receptor | 16 |
shunt attenuation | 16 |
reserve capacity | 16 |
right ventricular | 16 |
often present | 16 |
hepatic lipid | 16 |
superoxide dismutase | 16 |
organ transplant | 16 |
mitochondria isolated | 16 |
replacement therapy | 16 |
postoperative period | 16 |
green tea | 16 |
study found | 16 |
health care | 16 |
herbal medicine | 16 |
portal areas | 16 |
clinical outcome | 16 |
successful treatment | 16 |
positive chronic | 16 |
year period | 16 |
liver tumours | 16 |
high prevalence | 16 |
general hospital | 16 |
met een | 16 |
cells may | 15 |
study also | 15 |
young children | 15 |
western blotting | 15 |
liver disorders | 15 |
sustained virological | 15 |
clinical history | 15 |
portal inflammation | 15 |
biliary epithelial | 15 |
reported cases | 15 |
laboratory data | 15 |
clostridium difficile | 15 |
increased hepatic | 15 |
infl ow | 15 |
surgical treatment | 15 |
intrahepatic cpss | 15 |
nine patients | 15 |
high viral | 15 |
ionizable cationic | 15 |
initial treatment | 15 |
often occurs | 15 |
infectious causes | 15 |
rna positive | 15 |
left shift | 15 |
short term | 15 |
feeding tube | 15 |
four patients | 15 |
egfr signalling | 15 |
antithrombin iii | 15 |
may represent | 15 |
will also | 15 |
hepatic decompensation | 15 |
hepatocellular damage | 15 |
two cases | 15 |
first time | 15 |
nk cell | 15 |
included studies | 15 |
histologic findings | 15 |
disease patients | 15 |
significantly elevated | 15 |
mg cat | 15 |
protein synthesis | 15 |
acid secretion | 15 |
pulmonary embolism | 15 |
renal impairment | 15 |
proteomic analysis | 15 |
neutrophil extracellular | 15 |
gilead sciences | 15 |
gas exchange | 15 |
may reflect | 15 |
pugh score | 15 |
egf transgenic | 15 |
three months | 15 |
blood count | 15 |
small number | 15 |
may indicate | 15 |
studies demonstrated | 15 |
tract disease | 15 |
es cells | 15 |
liver tumor | 15 |
hepatic parenchymal | 15 |
weight ratio | 15 |
predisposing factors | 15 |
gall bladder | 15 |
american association | 15 |
esophageal sphincter | 15 |
expression profiles | 15 |
auxiliary liver | 15 |
patients whose | 15 |
also reported | 15 |
united kingdom | 15 |
laboratory values | 15 |
predictive factors | 15 |
three cases | 15 |
study reported | 15 |
liver transplants | 15 |
hepatitis virus | 15 |
intrahepatic shunts | 15 |
signs include | 15 |
two different | 15 |
fish oil | 15 |
undetectable hcv | 15 |
drug therapy | 15 |
base imbalance | 15 |
cord blood | 15 |
interferon alpha | 15 |
one month | 15 |
mm hg | 15 |
ex vivo | 15 |
venovenous bypass | 15 |
coagulation system | 15 |
treatment group | 15 |
glucose metabolism | 15 |
critical covid | 15 |
lobular dissecting | 14 |
lactic acidosis | 14 |
case reports | 14 |
biochemical abnormalities | 14 |
severe clinical | 14 |
eight patients | 14 |
hepatic biopsy | 14 |
serum half | 14 |
hepatic neoplasia | 14 |
warm ischemia | 14 |
position paper | 14 |
extrahepatic cholestasis | 14 |
significantly improved | 14 |
patients underwent | 14 |
gut microbiome | 14 |
serum hcv | 14 |
electrolyte imbalance | 14 |
common causes | 14 |
class i | 14 |
independent predictors | 14 |
diagnostic tool | 14 |
male patients | 14 |
major liver | 14 |
dna load | 14 |
epithelial cell | 14 |
cell response | 14 |
liver fluke | 14 |
usually present | 14 |
hcv antibody | 14 |
well known | 14 |
regression model | 14 |
inflammation may | 14 |
protein levels | 14 |
culture system | 14 |
tumor size | 14 |
histologic evidence | 14 |
heart disease | 14 |
regenerative nodules | 14 |
hepatitis may | 14 |
procent van | 14 |
specific treatment | 14 |
results indicate | 14 |
therapeutic strategies | 14 |
tubular necrosis | 14 |
primary disease | 14 |
hcv ns | 14 |
hepatocellular injury | 14 |
results demonstrate | 14 |
nigella sativa | 14 |
compensated cirrhosis | 14 |
oval cells | 14 |
activated charcoal | 14 |
autosomal recessive | 14 |
copyright holder | 14 |
therapeutic targets | 14 |
medical college | 14 |
monoclonal antibody | 14 |
lycium barbarum | 14 |
treatment duration | 14 |
child pugh | 14 |
also possible | 14 |
hepatocyte apoptosis | 14 |
aspiration pneumonia | 14 |
rights reserved | 14 |
fibroblast growth | 14 |
liver metastasis | 14 |
mouse liver | 14 |
strongly associated | 14 |
hypoxic hepatitis | 14 |
much higher | 14 |
acute cellular | 14 |
sustained viral | 14 |
coagulation abnormalities | 14 |
promoter region | 14 |
many patients | 14 |
lower esophageal | 14 |
six months | 14 |
acute fulminant | 14 |
white terriers | 14 |
time points | 14 |
organ transplantation | 14 |
cancer development | 14 |
significant changes | 14 |
human hepatoma | 14 |
hepatic clearance | 14 |
treatment options | 14 |
two dogs | 14 |
poor outcomes | 14 |
respiratory infections | 14 |
death liver | 14 |
life cycle | 14 |
abdominal ultrasonography | 14 |
portal circulation | 14 |
chiari syndrome | 14 |
clinical use | 14 |
egf induced | 14 |
similar results | 14 |
serum alanine | 14 |
natural killer | 14 |
portal scintigraphy | 14 |
long time | 14 |
room temperature | 14 |
bowel diarrhea | 14 |
gallbladder wall | 14 |
corticosteroid therapy | 14 |
high doses | 14 |
dissecting hepatitis | 14 |
inflammatory cell | 14 |
important cause | 14 |
diagnostic imaging | 14 |
lactic acid | 14 |
serum total | 14 |
normal level | 14 |
candida albicans | 14 |
failure acute | 14 |
medical university | 14 |
extrahepatic portosystemic | 14 |
large amounts | 14 |
made available | 14 |
protein expressions | 14 |
lamivudine treatment | 14 |
liver injuries | 14 |
gastroesophageal reflux | 13 |
significantly correlated | 13 |
kg orally | 13 |
higher levels | 13 |
per year | 13 |
transaminase levels | 13 |
hepatocyte damage | 13 |
drug administration | 13 |
reverse transcriptase | 13 |
treatment failure | 13 |
surgical intervention | 13 |
meld group | 13 |
practice guidelines | 13 |
tract obstruction | 13 |
negative chronic | 13 |
highly expressed | 13 |
patients will | 13 |
related acute | 13 |
clinical manifestation | 13 |
reactive protein | 13 |
positive correlation | 13 |
acute infection | 13 |
hbv infected | 13 |
rna negative | 13 |
pathological findings | 13 |
herbal medicines | 13 |
cancer cell | 13 |
flow cytometric | 13 |
control groups | 13 |
significant association | 13 |
international license | 13 |
parenteral nutrition | 13 |
myocardial infarction | 13 |
operating room | 13 |
patients compared | 13 |
pu pd | 13 |
partial thromboplastin | 13 |
hbeag loss | 13 |
affected animals | 13 |
acute viral | 13 |
randomized clinical | 13 |
liver specific | 13 |
water retention | 13 |
include vomiting | 13 |
alt elevation | 13 |
cell growth | 13 |
bariatric surgery | 13 |
degradation products | 13 |
transgenic non | 13 |
time period | 13 |
cerebral oedema | 13 |
liver sinusoidal | 13 |
tissue damage | 13 |
may prove | 13 |
adjunctive therapy | 13 |
crucial role | 13 |
bleeding tendency | 13 |
interferon alfa | 13 |
clotting times | 13 |
occurs within | 13 |
clinical research | 13 |
two times | 13 |
middle east | 13 |
ace expression | 13 |
single center | 13 |
hps patients | 13 |
pressure gradient | 13 |
vein hypoplasia | 13 |
liver samples | 13 |
death donors | 13 |
liver surgery | 13 |
dietary management | 13 |
alpinia officinarum | 13 |
serum samples | 13 |
bile salt | 13 |
two types | 13 |
higher incidence | 13 |
first year | 13 |
hemolytic anemia | 13 |
type patients | 13 |
siamese cats | 13 |
diagnostic test | 13 |
portopulmonary hypertension | 13 |
postoperative liver | 13 |
coronavirus infections | 13 |
improved survival | 13 |
time point | 13 |
potential causes | 13 |
blood gas | 13 |
study demonstrated | 13 |
glucose levels | 13 |
specific immune | 13 |
therapeutic effects | 13 |
high incidence | 13 |
oxidative injury | 13 |
first weeks | 13 |
dna copies | 13 |
hepatoma cell | 13 |
causes include | 13 |
diseased liver | 13 |
advanced hcc | 13 |
interface hepatitis | 13 |
low level | 13 |
successful outcome | 13 |
guided fine | 13 |
significant liver | 13 |
hepatic insulin | 13 |
bioartificial liver | 13 |
significantly greater | 13 |
energy charge | 13 |
immunosuppressive drugs | 13 |
alcohol abuse | 13 |
biliary atresia | 13 |
normal dogs | 13 |
cobas amplicor | 13 |
obeticholic acid | 13 |
intravenous injection | 13 |
also result | 13 |
brain death | 13 |
serum ast | 13 |
bilirubin concentrations | 13 |
multicenter study | 13 |
chronically infected | 13 |
wistar rats | 13 |
several weeks | 13 |
antiviral agents | 13 |
cats include | 13 |
every weeks | 13 |
also showed | 13 |
medical therapy | 13 |
higher doses | 13 |
hepatocyte proliferation | 13 |
voor levertransplantatie | 13 |
modified transudate | 13 |
hepatic sinusoids | 13 |
allograft dysfunction | 13 |
serum protein | 13 |
extracellular traps | 13 |
patients developed | 13 |
host cell | 13 |
hepatic lobules | 13 |
liver allograft | 13 |
acetaminophen toxicity | 13 |
feline pancreatic | 13 |
hbv quasispecies | 13 |
commonly reported | 13 |
machine perfusion | 13 |
term use | 12 |
pancreatic lipase | 12 |
mitochondrial membrane | 12 |
total body | 12 |
bile peritonitis | 12 |
toxoplasma gondii | 12 |
dcd donor | 12 |
histologic features | 12 |
factor xiii | 12 |
excessive activation | 12 |
tumor recurrence | 12 |
protein level | 12 |
clinical sign | 12 |
hcv proteins | 12 |
ventilation blood | 12 |
authors declare | 12 |
autoimmune diseases | 12 |
chc patients | 12 |
ill group | 12 |
solanum nigrum | 12 |
needle biopsies | 12 |
ifn therapy | 12 |
nach lebertransplantation | 12 |
extracorporeal liver | 12 |
venous ammonia | 12 |
main cause | 12 |
patients usually | 12 |
poor outcome | 12 |
patients suffering | 12 |
early detection | 12 |
normal controls | 12 |
protein diet | 12 |
may help | 12 |
ifn suppository | 12 |
cell mass | 12 |
diarrhea may | 12 |
univariate analysis | 12 |
age groups | 12 |
negative chb | 12 |
author funder | 12 |
serum hepatic | 12 |
year old | 12 |
zu einer | 12 |
collagen type | 12 |
abdominal wall | 12 |
showed significant | 12 |
immunohistochemical staining | 12 |
serious adverse | 12 |
histologically confirmed | 12 |
glycogen storage | 12 |
nuclear factor | 12 |
extrahepatic cpss | 12 |
usually occurs | 12 |
major hepatic | 12 |
elevated ast | 12 |
metabolic pathways | 12 |
may show | 12 |
chain fatty | 12 |
clinical evidence | 12 |
hemodynamic instability | 12 |
reference range | 12 |
cerebral blood | 12 |
cocker spaniels | 12 |
liver blood | 12 |
cationic lipids | 12 |
treatment strategies | 12 |
including liver | 12 |
dna damage | 12 |
two studies | 12 |
ultrasound examination | 12 |
ifn alfa | 12 |
creatinine clearance | 12 |
also important | 12 |
may induce | 12 |
fibrous tissue | 12 |
ggt activity | 12 |
granted medrxiv | 12 |
often found | 12 |
screening test | 12 |
clinical management | 12 |
lt patients | 12 |
confluent necrosis | 12 |
group iii | 12 |
bm cells | 12 |
simplex virus | 12 |
donor livers | 12 |
seven patients | 12 |
flapping tremor | 12 |
abdominal effusion | 12 |
adult cat | 12 |
may explain | 12 |
end stage | 12 |
induced hepatitis | 12 |
treated animals | 12 |
hepatotoxic drugs | 12 |
antioxidant enzymes | 12 |
chronic inflammatory | 12 |
cov infection | 12 |
hepatoprotective effect | 12 |
adsorbent recirculating | 12 |
infected pneumonia | 12 |
venous return | 12 |
health problem | 12 |
activator inhibitor | 12 |
independent predictor | 12 |
spider nevus | 12 |
failure induced | 12 |
pancreatic hypoplasia | 12 |
adefovir resistance | 12 |
function test | 12 |
com scientificreports | 12 |
ast alt | 12 |
renal blood | 12 |
failure may | 12 |
presenting cells | 12 |
prognostic value | 12 |
lamivudine resistance | 12 |
one week | 12 |
important roles | 12 |
esophageal variceal | 12 |
clinical picture | 12 |
protein intake | 12 |
fetal liver | 12 |
simple steatosis | 12 |
ischemic preconditioning | 12 |
ii clinical | 12 |
volume expansion | 12 |
clinical implications | 12 |
treatment may | 12 |
gi bleeding | 12 |
sectional study | 12 |
host cells | 12 |
concentration may | 12 |
surgical correction | 12 |
version posted | 12 |
waiting list | 12 |
posted june | 12 |
modified mrna | 12 |
poor prognostic | 12 |
upper quadrant | 12 |
novel protein | 12 |
major cause | 12 |
progressive liver | 12 |
control rats | 12 |
hepatic iron | 12 |
colorectal cancer | 12 |
platelet aggregation | 12 |
granulomatous hepatitis | 12 |
deceased patients | 12 |
animal studies | 12 |
congenital pancreatic | 12 |
enzyme elevations | 12 |
hydrostatic pressure | 12 |
nutritional status | 12 |
remains unclear | 12 |
microvascular dysplasia | 12 |
polycystic kidney | 12 |
potentially hepatotoxic | 12 |
systemic infection | 12 |
parietal cell | 12 |
intrapulmonary vascular | 12 |
may need | 12 |
hcv viral | 12 |
surgical procedure | 12 |
histopathologic evaluation | 12 |
initial dose | 12 |
exploratory celiotomy | 12 |
cd ko | 12 |
parenchymal liver | 12 |
cell migration | 12 |
vitro studies | 12 |
cirrhosis due | 12 |
coagulation profile | 12 |
nasogastric tube | 11 |
may improve | 11 |
statistical analysis | 11 |
critical illness | 11 |
fibrin degradation | 11 |
antigen presenting | 11 |
factor viii | 11 |
type plasminogen | 11 |
metabolic rate | 11 |
linear regression | 11 |
graft loss | 11 |
cell therapy | 11 |
previous study | 11 |
mononuclear phagocyte | 11 |
times daily | 11 |
clinical disease | 11 |
direct bilirubin | 11 |
stromal cells | 11 |
phase iii | 11 |
consecutive patients | 11 |
hepatic nodular | 11 |
first months | 11 |
data collection | 11 |
coagulation disorders | 11 |
log iu | 11 |
treated pigs | 11 |
previously described | 11 |
factors may | 11 |
usually associated | 11 |
positive group | 11 |
obtained using | 11 |
data show | 11 |
drug metabolism | 11 |
vascular invasion | 11 |
inflammatory drugs | 11 |
canine herpesvirus | 11 |
serum cholesterol | 11 |
success rate | 11 |
mg days | 11 |
post transplant | 11 |
exercise training | 11 |
type iii | 11 |
wall thickness | 11 |
neutralizing antibodies | 11 |
coronavirus infection | 11 |
concurrent diseases | 11 |
also contribute | 11 |
peg ifn | 11 |
invasive procedures | 11 |
cell injury | 11 |
one report | 11 |
medical treatment | 11 |
indocyanine green | 11 |
met name | 11 |
beneficial effect | 11 |
tissue injury | 11 |
ballooning degeneration | 11 |
herbal products | 11 |
retrospective cohort | 11 |
assess whether | 11 |
pancreatic transplantation | 11 |
quantitative rt | 11 |
positive predictive | 11 |
undergo liver | 11 |
monoclonal antibodies | 11 |
mainland china | 11 |
network consists | 11 |
fc treatment | 11 |
gene regulation | 11 |
resistant patients | 11 |
invasive diagnosis | 11 |
resistant mutation | 11 |
resonance imaging | 11 |
ast elevation | 11 |
adoptive transfer | 11 |
intrahepatic portal | 11 |
balloon catheter | 11 |
tissue cysts | 11 |
binding site | 11 |
reduce hepatic | 11 |
therapeutic options | 11 |
sustained response | 11 |
may suggest | 11 |
cell carcinoma | 11 |
controlled trials | 11 |
relatively low | 11 |
protein concentration | 11 |
intravenous infusion | 11 |
core expression | 11 |
tumor cell | 11 |
glutamine synthetase | 11 |
liver impairment | 11 |
human body | 11 |
biochemical response | 11 |
three cats | 11 |
gallbladder bile | 11 |
normal cats | 11 |
clinical relevance | 11 |
hepatitis caused | 11 |
rna levels | 11 |
bile secretion | 11 |
base balance | 11 |
van het | 11 |
patients admitted | 11 |
digestive tract | 11 |
hepatic mass | 11 |
sx amx | 11 |
mhc class | 11 |
resistant chronic | 11 |
liver pathology | 11 |
glutamyl transferase | 11 |
body ratio | 11 |
ketone body | 11 |
total liver | 11 |
ammonium biurate | 11 |
clinical severity | 11 |
prognostic indicators | 11 |
cats will | 11 |
risk patients | 11 |
human coronavirus | 11 |
less likely | 11 |
ph value | 11 |
ductus venosus | 11 |
chronic kidney | 11 |
blood products | 11 |
clinically normal | 11 |
inclusion criteria | 11 |
determined using | 11 |
total number | 11 |
acute severe | 11 |
often accompanied | 11 |
bedlington terrier | 11 |
infrahepatic ivc | 11 |
tract infections | 11 |
pivotal role | 11 |
milk thistle | 11 |
exploratory laparotomy | 11 |
critical role | 11 |
mrna delivery | 11 |
native liver | 11 |
helicobacter infection | 11 |
cationic lipid | 11 |
least two | 11 |
liver plays | 11 |
splenic vein | 11 |
treated mice | 11 |
body temperature | 11 |
postreperfusion syndrome | 11 |
term efficacy | 11 |
specific gene | 11 |
hcc cells | 11 |
young cats | 11 |
asymptomatic carriers | 11 |
organ systems | 11 |
glucose tolerance | 11 |
vacuolar hepatopathy | 11 |
resonance spectroscopy | 11 |
fuzheng huayu | 11 |
different degrees | 11 |
several months | 11 |
cell function | 11 |
mycobacterium avium | 11 |
drug toxicity | 11 |
cholangiocytes may | 11 |
increased intestinal | 11 |
graft rejection | 11 |
oxidative phosphorylation | 11 |
liver fibrogenesis | 11 |
pooled risk | 11 |
cause clinical | 11 |
clinical translation | 11 |
adenosine triphosphate | 11 |
blood supply | 11 |
frozen plasma | 11 |
awaiting liver | 11 |
right heart | 11 |
human studies | 11 |
icu admission | 11 |
outcome data | 11 |
type iv | 11 |
hepatic gene | 11 |
control animals | 11 |
aclf patients | 11 |
disease control | 11 |
supportive therapy | 11 |
national university | 11 |
pcr analysis | 11 |
severe infection | 11 |
randomly divided | 11 |
adverse event | 11 |
tissue repair | 11 |
histological examination | 11 |
disease processes | 11 |
specific proteins | 11 |
nucleic acids | 11 |
liver size | 11 |
urinary bladder | 11 |
blood tests | 11 |
factor receptor | 11 |
underwent liver | 11 |
hypertension may | 11 |
significant risk | 11 |
hbv reactivation | 11 |
negative correlation | 11 |
important clinical | 11 |
hepatoprotective effects | 11 |
die within | 11 |
virus replication | 11 |
often used | 11 |
resistant mutations | 11 |
factors including | 11 |
intestinal small | 11 |
diagnosis may | 11 |
hcv genotypes | 11 |
early recognition | 11 |
controlled clinical | 11 |
discharged patients | 11 |
thromboplastin time | 11 |
higher rates | 11 |
sterile inflammation | 10 |
good prognosis | 10 |
acute necrotizing | 10 |
hepatocyte injury | 10 |
bei der | 10 |
late stage | 10 |
und die | 10 |
hong kong | 10 |
existing chronic | 10 |
percutaneous liver | 10 |
small colon | 10 |
significant hepatic | 10 |
national health | 10 |
esophageal disease | 10 |
gastric bypass | 10 |
liver allografts | 10 |
aa patients | 10 |
low viral | 10 |
large intestine | 10 |
will develop | 10 |
canine adenovirus | 10 |
sirna delivery | 10 |
different liver | 10 |
one cat | 10 |
ca patients | 10 |
copper metabolism | 10 |
ast activity | 10 |
bei kindern | 10 |
duct ligation | 10 |
important part | 10 |
east respiratory | 10 |
novo lipogenesis | 10 |
hepatobiliary diseases | 10 |
cell counts | 10 |
protective effects | 10 |
wound healing | 10 |
cystic fibrosis | 10 |
host factors | 10 |
conjugated bilirubin | 10 |
plasma cells | 10 |
vascular dilation | 10 |
roche cobas | 10 |
genomic dna | 10 |
phase study | 10 |
untreated patients | 10 |
two cats | 10 |
liver donors | 10 |
baseline characteristics | 10 |
based therapy | 10 |
fine needle | 10 |
serum afp | 10 |
future studies | 10 |
infected cats | 10 |
patients awaiting | 10 |
venous thrombosis | 10 |
pcr positivity | 10 |
enzyme levels | 10 |
glutathione reductase | 10 |
related cld | 10 |
two hours | 10 |
will require | 10 |
guided biopsy | 10 |
molecular mechanism | 10 |
compared using | 10 |
concentrations may | 10 |
pugh class | 10 |
liver ischaemia | 10 |
reported outcome | 10 |
steroid hepatopathy | 10 |
viral persistence | 10 |
fi brosis | 10 |
relatively high | 10 |
lymphocytic cholangitis | 10 |
transcription factor | 10 |
liver mitochondria | 10 |
functional reserve | 10 |
doppler ultrasound | 10 |
higher serum | 10 |
congestive heart | 10 |
also increased | 10 |
transplant rhcv | 10 |
deficient mice | 10 |
many studies | 10 |
activated hsc | 10 |
biochemical findings | 10 |
immunodeficiency virus | 10 |
identified proteins | 10 |
direct effect | 10 |
cell infiltration | 10 |
preliminary study | 10 |
cell culture | 10 |
enterohepatic circulation | 10 |
mrna vaccines | 10 |
treated group | 10 |
jugular vein | 10 |
arterial partial | 10 |
healthy liver | 10 |
review article | 10 |
respiratory rate | 10 |
phagocyte system | 10 |
study population | 10 |
muscle wasting | 10 |
four cases | 10 |
high expression | 10 |
standard therapy | 10 |
possible mechanism | 10 |
liver perfusion | 10 |
hepatic tumors | 10 |
prognostic indicator | 10 |
recent advances | 10 |
support system | 10 |
may progress | 10 |
increased blood | 10 |
organ procurement | 10 |
studies reported | 10 |
sba concentrations | 10 |
higher rate | 10 |
age group | 10 |
seroconversion rate | 10 |
biopsy findings | 10 |
ammonia concentrations | 10 |
tumour proteins | 10 |
predictive factor | 10 |
specific ace | 10 |
impaired hepatic | 10 |
fresh frozen | 10 |
preliminary results | 10 |
human herpesvirus | 10 |
recently reported | 10 |
ncov infection | 10 |
copper levels | 10 |
corona virus | 10 |
adv therapy | 10 |
regenerating liver | 10 |
biliary complications | 10 |
rejection episodes | 10 |
inflammatory markers | 10 |
ill groups | 10 |
term prognosis | 10 |
gastrointestinal mucosa | 10 |
false neurotransmitters | 10 |
within years | 10 |
shunting vessel | 10 |
herpesvirus infection | 10 |
large sample | 10 |
dysfunction may | 10 |
leiden tot | 10 |
will increase | 10 |
nucleoside analogue | 10 |
liver parenchymal | 10 |
male gender | 10 |
hcc cases | 10 |
myocardial ischemia | 10 |
undetectable hbv | 10 |
cardiac failure | 10 |
feline cholangitis | 10 |
viral shedding | 10 |
total rna | 10 |
serum alkaline | 10 |
rat hepatic | 10 |
serum concentrations | 10 |
concurrent disease | 10 |
laboratory parameters | 10 |
control study | 10 |
svr rates | 10 |
clinical efficacy | 10 |
wedge biopsy | 10 |
salvia miltiorrhiza | 10 |
gi symptoms | 10 |
also lead | 10 |
gastric varices | 10 |
hbsag levels | 10 |
hepatic fibrogenesis | 10 |
single dose | 10 |
biliary cholangitis | 10 |
male rats | 10 |
primary graft | 10 |
cirrhotic patient | 10 |
patient population | 10 |
medical history | 10 |
diffuse hepatic | 10 |
testing positive | 10 |
pressure monitoring | 10 |
much less | 10 |
outflow obstruction | 10 |
hepatic pathology | 10 |
clotting factor | 10 |
routine laboratory | 10 |
transplant candidates | 10 |
carcinoma cells | 10 |
hepatic portal | 10 |
glucose level | 10 |
following criteria | 10 |
concomitant medications | 10 |
negative predictive | 10 |
prognostic marker | 10 |
reference interval | 10 |
nonspecific reactive | 10 |
highly sensitive | 10 |
shunt vessel | 10 |
kidney function | 10 |
aspiration cytology | 10 |
diagnostic workup | 10 |
months post | 10 |
ct scans | 10 |
rna interference | 10 |
kidney transplant | 10 |
severe diarrhea | 10 |
rat hepatocytes | 10 |
failure requiring | 10 |
mononuclear phagocytes | 10 |
proteins including | 10 |
synthetic function | 10 |
acute tubular | 10 |
ammonia level | 10 |
assessed using | 10 |
clinical results | 10 |
liver axis | 10 |
failure fulminant | 10 |
portal system | 10 |
lamivudine group | 10 |
abdominal mass | 10 |
high hbv | 10 |
binding sites | 10 |
idiosyncratic drug | 10 |
lnp systems | 10 |
small animal | 10 |
autoimmune liver | 10 |
cause hepatic | 10 |
chronic renal | 10 |
also significantly | 10 |
toxic metabolites | 10 |
bile canaliculi | 10 |
circulating levels | 10 |
branched chain | 10 |
resistant hbv | 10 |
serious complications | 10 |
meld scores | 10 |
antiviral drug | 10 |
basal core | 10 |
tested positive | 10 |
taken together | 10 |
serine protease | 10 |
sclerosing cholangitis | 10 |
dose dependent | 10 |
failure secondary | 10 |
plasma ammonia | 10 |
matrix metalloproteinase | 10 |
phase trial | 10 |
chronic gastritis | 10 |
data showed | 10 |
ko mice | 10 |
oxidative damage | 10 |
human serum | 10 |
contrast radiography | 10 |
fibrosis induced | 10 |
rarely reported | 10 |
recurrence rate | 10 |
target cells | 10 |
studies show | 10 |
severe patients | 10 |
immune dysfunction | 10 |
urea nitrogen | 10 |
liver weight | 10 |
fecal samples | 10 |
alcohol intake | 10 |
lung injury | 10 |
small molecule | 10 |
daily dose | 10 |
low levels | 10 |
poorer prognosis | 10 |
mg per | 10 |
bilirubin levels | 10 |
hepatic stem | 10 |
hbsag positive | 10 |
recurrent hepatitis | 10 |
relative risk | 10 |
hcc recurrence | 10 |
induces apoptosis | 10 |
supportive treatment | 10 |
will need | 10 |
per se | 10 |
serum proteins | 10 |
wide variety | 10 |
pleural effusions | 10 |
pulmonary disease | 10 |
bij kinderen | 10 |
included patients | 9 |
total hbv | 9 |
ameroid constrictor | 9 |
clinical application | 9 |
macrophage colony | 9 |
human genome | 9 |
reference value | 9 |
among others | 9 |
underlying chronic | 9 |
safety profile | 9 |
drug use | 9 |
histologic changes | 9 |
graft dysfunction | 9 |
vertical transmission | 9 |
survival times | 9 |
patients experienced | 9 |
antiviral efficacy | 9 |
storage disease | 9 |
immunosorbent assay | 9 |
quasispecies complexity | 9 |
stent placement | 9 |
age range | 9 |
socioeconomically disadvantaged | 9 |
master regulator | 9 |
hepatic vascular | 9 |
immune suppression | 9 |
mice treated | 9 |
severe form | 9 |
least weeks | 9 |
intestinal barrier | 9 |
may account | 9 |
anemia may | 9 |
gene editing | 9 |
previous reports | 9 |
continuous infusion | 9 |
tumor suppressor | 9 |
acid therapeutics | 9 |
mortality risk | 9 |
expression data | 9 |
german shepherd | 9 |
meconium impactions | 9 |
related complications | 9 |
developing countries | 9 |
glycyrrhiza glabra | 9 |
cerebral hyperemia | 9 |
arterial flow | 9 |
oval cell | 9 |
intravenous administration | 9 |
perfusion pressure | 9 |
hyperdynamic circulation | 9 |
signifi cantly | 9 |
eine lebertransplantation | 9 |
vivo studies | 9 |
dawley rats | 9 |
older age | 9 |
pediatric patients | 9 |
hcv positive | 9 |
cell hepatitis | 9 |
uniquely expressed | 9 |
congenital extrahepatic | 9 |
tissue factor | 9 |
kg bw | 9 |
protease inhibitors | 9 |
noncirrhotic portal | 9 |
hepatitis associated | 9 |
cholangitis cholangiohepatitis | 9 |
inflammatory disease | 9 |
liver progenitor | 9 |
cytomegalovirus infection | 9 |
adv resistance | 9 |
transcriptional activity | 9 |
study suggested | 9 |
severe complications | 9 |
patients respectively | 9 |
dissection stage | 9 |
currently available | 9 |
copper excretion | 9 |
surgical techniques | 9 |
kans op | 9 |
negative results | 9 |
risk assessment | 9 |
necrotizing pancreatitis | 9 |
serum transaminase | 9 |
late stages | 9 |
target cell | 9 |
cd regulatory | 9 |
patients often | 9 |
studies suggest | 9 |
focal lesions | 9 |
clinically ill | 9 |
measured using | 9 |
cardiac arrest | 9 |
acute abdominal | 9 |
splenic volume | 9 |
marked increases | 9 |
mouse models | 9 |
ulcer disease | 9 |
cell populations | 9 |
supplementary table | 9 |
approximately half | 9 |
thyroid hormone | 9 |
proinflammatory cytokines | 9 |
may persist | 9 |
also present | 9 |
postoperative complications | 9 |
interquartile range | 9 |
pathogenic human | 9 |
islet cell | 9 |
underlying mechanisms | 9 |
pancreatic inflammation | 9 |
repressed expression | 9 |
liver volume | 9 |
least months | 9 |
effective dose | 9 |
severe type | 9 |
findings suggest | 9 |
experimentally induced | 9 |
tyrosine kinase | 9 |
peiu ml | 9 |
sd rats | 9 |
alt values | 9 |
hospital mortality | 9 |
biochemical tests | 9 |
venous congestion | 9 |
care management | 9 |
disease include | 9 |
uk biobank | 9 |
canine liver | 9 |
adult dogs | 9 |
specific therapy | 9 |
social support | 9 |
renal transplantation | 9 |
potential role | 9 |
advanced disease | 9 |
prothrombin activity | 9 |
group compared | 9 |
hepatic neoplasms | 9 |
disease clinical | 9 |
hcv related | 9 |
mechanisms involved | 9 |
also studied | 9 |
also play | 9 |
metabolic disorder | 9 |
young dog | 9 |
cairn terriers | 9 |
polycystic disease | 9 |
many factors | 9 |
blood levels | 9 |
portacaval shunts | 9 |
er stress | 9 |
categorical variables | 9 |
potentiated sulfonamides | 9 |
kg daily | 9 |
year graft | 9 |
china clinical | 9 |
raised alt | 9 |
western medicine | 9 |
lung disease | 9 |
histopathological changes | 9 |
renal transplant | 9 |
clinical improvement | 9 |
liver lobes | 9 |
diagnostic approach | 9 |
days later | 9 |
dog disseminated | 9 |
trace metals | 9 |
five days | 9 |
graft function | 9 |
occur secondary | 9 |
infected children | 9 |
culture medium | 9 |
pancreatic cancer | 9 |
barr virus | 9 |
normal serum | 9 |
failing liver | 9 |
shunt ligation | 9 |
lipid profile | 9 |
initial viral | 9 |
derived cells | 9 |
physiological conditions | 9 |
ist die | 9 |
inferior vena | 9 |
blood ketone | 9 |
cause severe | 9 |
significantly inhibited | 9 |
cell type | 9 |
zinc finger | 9 |
negative group | 9 |
within one | 9 |
prolonged pt | 9 |
retrospective review | 9 |
soft tissue | 9 |
higher level | 9 |
factors affecting | 9 |
immune tolerance | 9 |
mesenchymal stromal | 9 |
blood ph | 9 |
venous flow | 9 |
data analysis | 9 |
died within | 9 |
calcineurin inhibitors | 9 |
six cases | 9 |
clinical setting | 9 |
renal replacement | 9 |
activated partial | 9 |
hepatic differentiation | 9 |
readily available | 9 |
cytokine production | 9 |
renal tubular | 9 |
related cirrhosis | 9 |
gel electrophoresis | 9 |
cell surface | 9 |
leading cause | 9 |
invasive procedure | 9 |
cardiovascular disease | 9 |
see additional | 9 |
radiographs may | 9 |
hepatectomy liver | 9 |
flow velocity | 9 |
multiorgan failure | 9 |
pulmonary capillaries | 9 |
statistical difference | 9 |
ultrasound guidance | 9 |
scoring systems | 9 |
immune activation | 9 |
immediate postoperative | 9 |
und oder | 9 |
gradient centrifugation | 9 |
creative commons | 9 |
cells expressing | 9 |
situ hybridization | 9 |
cell population | 9 |
highly variable | 9 |
provide evidence | 9 |
highly digestible | 9 |
continuous variables | 9 |
fluorescence intensity | 9 |
hepatic energy | 9 |
like growth | 9 |
clinically relevant | 9 |
antimicrobial peptides | 9 |
tumour growth | 9 |
hbsag clearance | 9 |
albumin level | 9 |
total serum | 9 |
disease occurs | 9 |
plasma protein | 9 |
bilirubin concentration | 9 |
interval ci | 9 |
poorly understood | 9 |
partial response | 9 |
precise diagnosis | 9 |
portal vasculature | 9 |
clinical examination | 9 |
lower extremities | 9 |
frequently used | 9 |
significant effect | 9 |
hepatic transplantation | 9 |
takes place | 9 |
nash patients | 9 |
body fluid | 9 |
often associated | 9 |
also investigated | 9 |
hepatic synthesis | 9 |
log drop | 9 |
plasma separation | 9 |
examination may | 9 |
mrna transcription | 9 |
ifn alpha | 9 |
clinical syndrome | 9 |
cellular proliferation | 9 |
trace elements | 9 |
portal flow | 9 |
knockout mice | 9 |
dcd lts | 9 |
four weeks | 9 |
renal azotemia | 9 |
cerebral hernia | 9 |
particular attention | 9 |
several mechanisms | 9 |
freshly isolated | 9 |
patients surviving | 9 |
severe hypoxemia | 9 |
organ damage | 9 |
serum uric | 9 |
hazard ratio | 9 |
evidence suggests | 9 |
following hepatic | 9 |
acid synthesis | 9 |
viral rna | 9 |
metastatic disease | 9 |
elderly patients | 9 |
delayed gastric | 9 |
hcv specific | 9 |
cytometric analysis | 9 |
first step | 9 |
healthcare workers | 9 |
increased production | 9 |
hiv aids | 9 |
bei patienten | 9 |
dorsal recumbency | 9 |
controlled studies | 9 |
antigen presentation | 9 |
intravenous albumin | 9 |
feeding tubes | 9 |
murine models | 9 |
almost exclusively | 9 |
studies revealed | 9 |
portacaval shunt | 9 |
cellular immune | 9 |
statistical significance | 9 |
therapeutic potential | 9 |
three types | 9 |
renal vasoconstriction | 9 |
maintenance therapy | 9 |
toxic effects | 9 |
signs associated | 9 |
red cells | 9 |
canine hepatitis | 9 |
high affinity | 9 |
diabetic rats | 9 |
molecular biology | 9 |
adverse reactions | 9 |
cell tumor | 9 |
test may | 9 |
current study | 9 |
metabolic diseases | 9 |
matrix metalloproteinases | 9 |
pattern recognition | 9 |
medrxiv preprint | 9 |
enteral feeding | 9 |
major risk | 9 |
like cells | 9 |
transplant centers | 9 |
body condition | 9 |
treg cells | 9 |
virus disease | 9 |
fold increase | 9 |
investigate whether | 9 |
independently associated | 9 |
nosocomial infection | 9 |
artery disease | 9 |
serum activities | 9 |
feline leukemia | 9 |
ifn injection | 9 |
anal sac | 9 |
analysis using | 8 |
th century | 8 |
dogs treated | 8 |
three different | 8 |
gastric ulcer | 8 |
still unclear | 8 |
receptor antagonists | 8 |
transplant center | 8 |
may prevent | 8 |
soluble vitamins | 8 |
ill cats | 8 |
author prefers | 8 |
reticulum stress | 8 |
serum biomarkers | 8 |
following conditions | 8 |
single nucleotide | 8 |
small numbers | 8 |
metabolic factors | 8 |
combination group | 8 |
hospital admission | 8 |
nafld progression | 8 |
apoptotic cells | 8 |
viral breakthrough | 8 |
bacterial culture | 8 |
injury caused | 8 |
entire liver | 8 |
chinese patients | 8 |
glutamic acid | 8 |
four cats | 8 |
significant number | 8 |
rna titer | 8 |
alf patients | 8 |
irish wolfhounds | 8 |
regulated protein | 8 |
multivariable logistic | 8 |
total protein | 8 |
rank test | 8 |
will lead | 8 |